Technology Prognosis

tracking technologies before you have to make a decision

Crysvita (Burosumab-twza)

February 1, 2019

Crysvita is a subcutaneously injected recombinant fully human monoclonal IgG1 antibody against fibroblast growth factor 23 (FGF23) intended for treatment X-linked hypophosphatemia (XLH) in adults and children aged 1 year and older. Crysvita is designed to bind to and inhibit excessive biological activity of FGF23. By blocking excess FGF23 in patients with XLH, Crysvita is intended to restore normal phosphate reabsorption from the kidney and increase the production of vitamin D, which enhances intestinal absorption of phosphate and calcium.